| Index | — | P/E | — | EPS (ttm) | -2.25 | Insider Own | 10.35% | Shs Outstand | 23.24M | Perf Week | -12.23% |
| Market Cap | 315.15M | Forward P/E | — | EPS next Y | -0.47 | Insider Trans | 0.00% | Shs Float | 6.60M | Perf Month | -11.78% |
| Enterprise Value | 344.15M | PEG | — | EPS next Q | -0.05 | Short Float | 0.28% | Perf Quarter | -18.75% | ||
| Income | -209.00M | P/S | 3.46 | EPS this Y | — | Short Ratio | 2.87 | Perf Half Y | -38.42% | ||
| Sales | 91.00M | P/B | 3.80 | EPS next Y | — | ROA | -44.64% | Short Interest | 18.16K | Perf YTD | -48.32% |
| Book/sh | 3.57 | P/C | 1.13 | EPS next 5Y | — | ROE | -153.78% | 52W High | 34.50 -60.70% | Perf Year | -58.56% |
| Cash/sh | 12.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -48.87% | 52W Low | 13.46 0.74% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 36.01% 108.07% | Gross Margin | 81.56% | Volatility | 3.16% 3.20% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 3.78 | EPS Y/Y TTM | — | Oper. Margin | -218.70% | ATR (14) | 0.70 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.18 | Sales Y/Y TTM | 68.52% | Profit Margin | -228.60% | RSI (14) | 36.45 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.22 | EPS Q/Q | -34.88% | SMA20 | -10.13% | Beta | 1.27 | Target Price | 46.50 |
| Payout | 0.00% | Debt/Eq | 3.71 | Sales Q/Q | 37.50% | SMA50 | -14.17% | Rel Volume | 0.79 | Prev Close | 14.46 |
| Employees | 767 | LT Debt/Eq | 1.10 | Earnings | Mar 31 | SMA200 | -32.46% | Avg Volume | 7.01K | Price | 13.56 |
| IPO Date | Jan 24, 2025 | Option/Short | No / Yes | EPS/Sales Surpr. | -492.58% -16.14% | Net Debt/EBITDA | — | Volume | 5,515 | Change | -6.22% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-24-26 | Initiated | Deutsche Bank | Buy | $40 |
| Dec-04-25 | Initiated | Oppenheimer | Outperform | $45 |
| Nov-24-25 | Initiated | Truist | Buy | $51 |
| Nov-05-25 | Reiterated | Piper Sandler | $48 |
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 91 | 78 | 136 | 31 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 17 | 18 | 4 | 4 | — | — | — | — | — | |
| Gross Profit | 74 | 59 | 132 | 27 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 91 | 73 | 53 | 53 | — | — | — | — | — | |
| Research and Development | 183 | 151 | 132 | 100 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | -3 | — | — | — | — | — | |
| Operating Income | -199 | -164 | -51 | -123 | — | — | — | — | — | |
| Interest Expense | 8 | 7 | 9 | 14 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 4 | 5 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | -207 | -167 | -55 | -132 | — | — | — | — | — | |
| Income Taxes | 2 | 1 | 1 | -1 | — | — | — | — | — | |
| Consolidated Net Income | -209 | -168 | -56 | -131 | — | — | — | — | — | |
| Net Income From Continuing Operations | -209 | -168 | -56 | -131 | — | — | — | — | — | |
| Net Income | -209 | -168 | -56 | -131 | — | — | — | — | — | |
| EPS (Recurring) | -2.25 | -1.89 | -0.74 | -7.41 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.25 | -1.89 | -0.74 | -7.41 | — | — | — | — | — | |
| EPS (Diluted) | -2.25 | -1.89 | -0.74 | -7.41 | — | — | — | — | — | |
| EBITDA | -188 | -152 | -33 | -105 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.86 | 29.94 | — | — | — | — | — | — | — | |
| Gross Margin | 81.32 | 75.64 | 97.06 | 87.10 | — | — | — | — | — | |
| Operating Margin | -218.68 | -210.26 | -37.50 | -396.77 | — | — | — | — | — | |
| Net Margin | -229.67 | -215.38 | -41.18 | -422.58 | — | — | — | — | — | |
| Shares Outstanding | 93 | 89 | 76 | 18 | — | — | — | — | — | |
| Market Capitalization | 1,261 | 2,335 | — | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zhai Yifan | Chief Medical Officer | May 21 '26 | Option Exercise | 0.00 | 188,321 | 0 | 1,193,569 | May 22 |
| Yang Dajun | Chairman and CEO | May 21 '26 | Option Exercise | 0.00 | 188,321 | 0 | 1,193,569 | May 22 |